ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Session » Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1303
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Abstract Number: 1304
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Abstract Number: 1305
Clinical Joint Involvement Is Decisive For Radiographic Progression
Abstract Number: 1306
Do Sustained Clinical Remission and Sustained Low Disease Activity Equally Predict Functional Status In Early Rheumatoid Arthritis?
Abstract Number: 1307
Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics
Abstract Number: 1308
Low Accuracy Of Radiograph Reports In Identifying Patients With Rheumatoid Arthritis In The Veterans Affairs Rheumatoid Arthritis Registry
Abstract Number: 1309
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Abstract Number: 1310
Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Abstract Number: 1311
Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort
Abstract Number: 1312
A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized  Trial
Abstract Number: 1313
Tobacco Exposure Is Associated With Radiographic Damage In Hispanic and African American Rheumatoid Arthritis Patients
Abstract Number: 1314
Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis
Abstract Number: 1315
14-3-3η and Its Auto-Antibodies Predict Response To Anti-TNF Therapy
Abstract Number: 1316
MMP3 As a Predictor Identifying a Subgroup Of Rheumatoid Patients Who Are Successfully Treated With Methotrexate (MTX) Alone But Still Subject To Radiographic Progression
Abstract Number: 1317
Methotrexate Optimization (ie introduction during the first 3 months and with dose escalation at 6 months at least at 20mg/w or 0.3mg/kg/w) Is Associated With Better Clinical Outcomes In Daily Practice: Results From The Espoir Cohort
Abstract Number: 1318
Prevalence and Impact Of Soft Tissue Manifestations In Early Inflammatory Arthritis: Results From The Canadian Early Arthritis Cohort
Abstract Number: 1319
Diagnostic Value Of Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Abstract Number: 1320
Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Abstract Number: 1321
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Abstract Number: 1322
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Abstract Number: 1323
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Abstract Number: 1324
Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents
Abstract Number: 1325
A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients
Abstract Number: 1326
Discriminative Metabolite Profiling Of Synovial Fluid In Rheumatoid Arthritis Compared To Osteoarthritis
Abstract Number: 1327
Autoantibodies To Citrullinated Proteins Associate With Bone Destruction Marker and Are Modulated By First Anti Rheumatic Treatment In Early Rheumatoid Arthritis
Abstract Number: 1329
Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Abstract Number: 1330
Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies
Abstract Number: 1331
Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha
Abstract Number: 1332
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Abstract Number: 1333
The Impact Of Menopause In Rheumatoid Arthritis Activity
Abstract Number: 1334
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Abstract Number: 1335
Sarcopenia Is Associated With Joint Damage In Rheumatoid Arthritis patients a Cross Sectional Study In a Peruvian Population
Abstract Number: 1336
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Abstract Number: 1337
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Abstract Number: 1338
Time To Institution Of Disease Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Abstract Number: 1339
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Abstract Number: 1340
Functional Disability and Quality Of Life Are More Likely Improved In Patients With Rheumatoid Arthritis Who Achieved The New ACR/EULAR Remission Criteria Compared To DAS28 Remission In Daily Practice
Abstract Number: 1341
Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users
Abstract Number: 1342
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Abstract Number: 1343
Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort
Abstract Number: 1344
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Abstract Number: 1345
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
Abstract Number: 1346
Drug Free Holiday In Patients With Rheumatoid Arthritis (RA): patients’ Opinion
Abstract Number: 1347
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
Abstract Number: 1348
Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
Abstract Number: 1349
High Rate Of Improvement In Serum Matrix Metalloproteinase-3 Levels At 4 Weeks Predict Remission At 52 Weeks In RA Patients With Adalimumab Therapy
Abstract Number: 1350
Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Abstract Number: 1351
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Abstract Number: 1352
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Abstract Number: 1353
Remission After Twelve Month Of Treatment In The Prague Early Rheumatoid Arhritis Cohort
Abstract Number: 1354
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Abstract Number: 1355
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Abstract Number: 1356
Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Abstract Number: 1357
Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
Abstract Number: 1358
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Abstract Number: 1359
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Abstract Number: 1360
Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients
Abstract Number: 1361
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Abstract Number: 1362
Isymind Significantly Reduces MTX-Induced Nausea In a Pilot Trial
Abstract Number: 1363
Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study
Abstract Number: 1364
Detection of Latent Tuberculosis Infection in Rheumatologic Diseases Before Anti-TNFα Therapy: Tuberculin Skin Test Versus IFN-γ Assay
Abstract Number: 1365
Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Abstract Number: 1366
Abdominal Adiposity and Body Composition In Rheumatoid Arthritis: Relation With Disease Characteristics In A Case-Control Study
Abstract Number: 1367
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
Abstract Number: 1368
The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis
Abstract Number: 1369
Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease
Abstract Number: 1370
Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases
Abstract Number: 1371
Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Abstract Number: 1372
Do We Really Identify Latent Tuberculosis? Comparison Of The Performance Of Tuberculin Skin Test and Interferon Gamma Release Assay Before Biologics: A Systematic Review and Meta-Analysis

« View all sessions from this meeting

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology